Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experience.
Joana DesterroDonal P McLornanNatalia Curto-GarciaJennifer O'SullivanSamah AlimamClodagh KeohaneClaire WoodleyYvonne FrancisShahram KordastiDeepti H RadiaClaire N HarrisonPublished in: British journal of haematology (2019)
Standard first-line therapy choice for essential thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFNα)-2a/2b and pegylated (PEG)-IFN-α-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the 'real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFNα or (PEG)-IFN-α-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.
Keyphrases
- end stage renal disease
- low dose
- newly diagnosed
- ejection fraction
- chronic kidney disease
- immune response
- peritoneal dialysis
- type diabetes
- prognostic factors
- primary care
- cardiovascular disease
- patient reported outcomes
- stem cells
- drug delivery
- coronary artery disease
- machine learning
- randomized controlled trial
- preterm infants
- cross sectional
- patient reported
- cell therapy
- preterm birth
- study protocol
- percutaneous coronary intervention